 This is a single center phase III open label, dose escalating, exploratory study assessing safety and efficacy of IdeS Hansa Medical, Lund, Sweden given immediately prior to kidney transplantation. We hope that IdeS will help eliminate DSAs in HS patients who are DSA and flow cytometry FCMX crossmatch at time of transplant. We plan to enroll a total of 20 patients. Patients will be followed for 6 months post administration of IdeS. 